Anil Khandelwal, MD
Adolescent Medicine · Plainfield, NJNPI 1669630356
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 28.5% of the total. 2025 is the largest year on record at $1,601, 5.7 times the $282 reported in 2019. Among adolescent medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $36.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Viiv Healthcare Company$1K
- Amgen$491
- Gilead$469
- AstraZeneca$449
- GSK$226
- plus $1K from 14 others
What the payments were for
- Food & beverage$5,25598%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $1,527 |
| Viiv Healthcare Company | 58 | $1,043 |
| Amgen | 5 | $491 |
| Gilead | 24 | $469 |
| AstraZeneca | 4 | $449 |
| GSK | 2 | $226 |
| Novo Nordisk | 5 | $182 |
| Merck | 12 | $180 |
| Madrigal Pharmaceuticals | 1 | $135 |
| Theratechnologies Inc. | 8 | $127 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Janssen Products, LP | 1 | $100 |
| Boehringer Ingelheim | 1 | $84 |
| Cequr Corporation | 1 | $54 |
| Lilly USA, LLC | 3 | $49 |
| Exact Sciences | 2 | $45 |
| Johnson & Johnson | 1 | $23 |
| Pfizer | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,355 in reported general payments places this provider in the 95th percentile of 156 adolescent medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 216 | $849,035 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $52,024 |
| DovatoDolutegravir Sodium/Lamivudine | 16 | $45,091 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $43,494 |
| PrezistaDarunavir | 16 | $32,211 |
| TivicayDolutegravir Sodium | 14 | $30,910 |
| RybelsusSemaglutide | 21 | $27,439 |
| TrulicityDulaglutide | 15 | $22,257 |
| MounjaroTirzepatide | 14 | $13,203 |
| FarxigaDapagliflozin Propanediol | 12 | $11,947 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $11,619 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,670 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $2,992 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $2,868 |
| Atorvastatin Calcium | 167 | $1,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $469 | $901,060229 claims |
| Viiv Healthcare CompanyDovato, Triumeq, Tivicay | $1,043 | $119,49442 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $49 | $35,46029 claims |
| Novo NordiskRybelsus | $182 | $27,43921 claims |
| AstraZenecaFarxiga | $449 | $11,94712 claims |
| MerckJanumet | $180 | $11,61913 claims |
| GSKBreo Ellipta | $226 | $4,67011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 adolescent medicine providers in New Jersey.
Other adolescent medicine in Plainfield
- Silvio QuagliaMillburn$101K
- Randy TalamayanLakewood$15K
- Thomas PitosciaMillburn$11K
- Susan Brill-GoldbergNew Brunswick$7K
- Amita PatelElizabeth$7K
- Robert JohnsonNewark$6K
- Richard ReutterLong Branch$6K
- John CavutoWestfield$5K
- Malgorzata KortowskaClifton$3K
- Glenn PalskyLawrenceville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.